Compare KMPR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KMPR | IOVA |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | 7400 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | 2008 |
| Metric | KMPR | IOVA |
|---|---|---|
| Price | $29.83 | $3.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $47.67 | $9.00 |
| AVG Volume (30 Days) | 817.5K | ★ 13.7M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $47.74 |
| Revenue Next Year | $4.35 | $40.31 |
| P/E Ratio | $14.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.74 | $1.67 |
| 52 Week High | $65.32 | $5.63 |
| Indicator | KMPR | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 51.80 |
| Support Level | $28.91 | $2.05 |
| Resistance Level | $32.01 | $4.27 |
| Average True Range (ATR) | 1.31 | 0.27 |
| MACD | -0.25 | -0.00 |
| Stochastic Oscillator | 29.86 | 41.95 |
Kemper Corp is an insurance holding company that offers complementary insurance products through its subsidiaries, including personal and commercial automobile insurance to consumers in targeted markets and industries. Kemper also offers life and other insurance solutions based on the needs of its clients. The company offers its insurance products through a vast network of agents and brokers, mainly under the Kemper Auto and Kemper Life brands. It has two operating segments: Specialty Property & Casualty Insurance and Life Insurance. The majority of the company's revenue is generated from the Specialty Property & Casualty Insurance segment, whose principal products are specialty personal automobile and commercial automobile insurance. Geographically, it operates only in the United States.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.